Warning of nationwide Mounjaro weight-loss jab shortage ahead of UK price hike
Weight loss pesticide Mounjaro’nun an increase in the sale of high street companies bots, Lloyds Pharmacy and SuperDrug, including major pharmacies caused trouble.
The increase in demand comes after Eli Lilly, who produces Mounjaro, has announced that it is to increase the price of the drug in England by 170 percent since September.
This means that the highest dose of the drug will rise from £ 122 to £ 330.
On social media, many users, Eli Lilly and the National Pharmacy Association (NPA), despite a warning so that they do not give a mass order, they have stocked drugs to avoid the initial price increase.
The situation caused many pharmacies to feel the effect.
SuperDrug said that on Wednesday, Mounjaro on his website is not in stock because of a “national famine”. In a statement IndependentThe company said: uz We are currently working hard to fulfill all the orders placed for Mounjaro and we hope to start accepting new customer orders next week.
“Due to extremely high demand throughout the country, we are experiencing delays with Mounjaro stock. In order to ensure the continuity of care, we prioritize the drug orders of the current super physician patients who currently use our weight loss services.”
Lloyds Pharmacy said on the website that high -dosage items of 10mg, 12.5mg and 15mg are not in stock for new recipes, Boots Online Doctor showed that 7.5mg, 10mg, 12.5mg or 15mg PENS.
Before users rise to higher dosages, it usually starts at a weekly dose of 2.5 mg as part of a weight loss plan.
Well, the second largest pharmacy chain in the UK, said Wel Pharmacy, Mounjaro, because of the increase in demand, “intermittent” from wholesalers, he said.
The company’s clinical product and innovation manager Mital Thakrar, Independent: “We are working hard with our wholesalers and manufacturers to maintain stock supply in well stores and we are currently staying in Mounjaro stocks.”
The situation also affected online pharmacies.
Pharmacy 2U said that after the announcement of the price increase, he saw a “significant short -term fluctuation, but the increase was calmed and prioritized existing patients.
Simple online pharmacy, Mounjaro’yu paused to sell to new patients, and at the same time to stop collective sales of sales per patient with a four -week supply, he said. He said that he had “sufficient” supply in all dosages to meet the prescriptions again.
Pharmacy, a cheaper alternative to opponent weight loss drug wegovy or more people who see more people, he said. Wegovy, who cost £ 85 per month, is recommended for a week between the two products.
Last week, Wegovy’s sales in a weight loss supplier increased by 2,600 percent after Mounjaro price increase.
Abdal Alvi, the chief clinical manager of Simple Online Healthcare, said that the pharmacy received demand for all GLP-1 drugs containing Wegovy and Mounjaro.
The increase in demand led to concerns in the pharmacy industry, including the NPA, which he said that he was aware of “closing or preventing orders for higher doses” before the wholesalers’ price increase.
President Olivier Picard added that collective purchase may have a “significant impact üzerinde on the supply, and at the same time, as part of the weight loss management, the seller may pose a potential risk for patient safety through a possible lack of regular controls.
Patients urged the UK to avoid unlicensed sellers who could sell counterfeit drugs that do not meet safety standards.
Mr. Picard, who runs his own pharmacy, said, “The situation is now terrible. I have patients from online pharmacies and other bricks and mortar pharmacies, calling, ‘Do you need a supply and my supplier is no stock’.
“I think wholesalers are completely overwhelmed by the demand of people trying to buy Mounjaro.”
Eli Lilly said it helps to manage the supply and access the patient for the providers who order stock.
A spokesman told Independent: “There are legal protections implemented by the health products regulatory agency to prevent inappropriate stock of drugs by providers.
“We encourage patients to order only according to their current treatment plans to reduce the risk of localized disruption.”
The company’s decision to increase the price reflected US President Donald Trump’s political pressure of US President Donald Trump to keep the prices more closely with other European markets to keep the Americans low.
